Yunjing Zeng

Xinqiao, 400037, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

A Bone Marrow-Targeted Nanomodulator as a Histone Lactylation Inhibitor for Reversing Immune Tolerance in Multiple Myeloma.

A Bone Marrow-Targeted Nanomodulator as a Histone Lactylation Inhibitor for Reversing Immune Tolerance in Multiple Myeloma.

Journal: ACS nano

Published: April 21, 2026

Erratum: [Corrigendum] Inhibition of microRNA-221-5p induces osteogenic differentiation by directly targeting smad3 in myeloma bone disease mesenchymal stem cells.

Erratum: [Corrigendum] Inhibition of microRNA-221-5p induces osteogenic differentiation by directly targeting smad3 in myeloma bone disease mesenchymal stem cells.

Journal: Oncology letters

Published: April 01, 2026

A novel prognostic nomogram based on imaging and molecular parameters for newly diagnosed extranodal natural killer/T-cell lymphoma patients.

A novel prognostic nomogram based on imaging and molecular parameters for newly diagnosed extranodal natural killer/T-cell lymphoma patients.

Journal: Haematologica

Published: February 26, 2024

Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas.

Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas.

Journal: International journal of hematology

Published: August 03, 2023

Significance of PPARA as a Treatment Target for Chronic Lymphocytic Leukemia.

Significance of PPARA as a Treatment Target for Chronic Lymphocytic Leukemia.

Journal: PPAR research

Published: February 08, 2023

Human circulating small non-coding RNA signature as a non-invasive biomarker in clinical diagnosis of acute myeloid leukaemia.

Human circulating small non-coding RNA signature as a non-invasive biomarker in clinical diagnosis of acute myeloid leukaemia.

Journal: Theranostics

Published: October 20, 2022

Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia.

Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia.

Journal: Acta biomaterialia

Published: August 02, 2022

The Machine-Learning-Mediated Interface of Microbiome and Genetic Risk Stratification in Neuroblastoma Reveals Molecular Pathways Related to Patient Survival.

The Machine-Learning-Mediated Interface of Microbiome and Genetic Risk Stratification in Neuroblastoma Reveals Molecular Pathways Related to Patient Survival.

Journal: Cancers

Published: April 15, 2022

Corrigendum to: Microfluidic enrichment of plasma cells improves treatment of multiple myeloma.

Corrigendum to: Microfluidic enrichment of plasma cells improves treatment of multiple myeloma.

Journal: Molecular oncology

Published: January 05, 2021

Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.

Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.

Journal: Biomarker research

Published: May 22, 2020

miR-203a-3p.1 is involved in the regulation of osteogenic differentiation by directly targeting Smad9 in MM-MSCs.

miR-203a-3p.1 is involved in the regulation of osteogenic differentiation by directly targeting Smad9 in MM-MSCs.

Journal: Oncology letters

Published: November 20, 2018

Inhibition of microRNA-221-5p induces osteogenic differentiation by directly targeting smad3 in myeloma bone disease mesenchymal stem cells.

Inhibition of microRNA-221-5p induces osteogenic differentiation by directly targeting smad3 in myeloma bone disease mesenchymal stem cells.

Journal: Oncology letters

Published: November 12, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026